Singapore, March 4 -- China-based WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced the launch of its innovative technology platform, EffiX, a proprietary E. coli expression system engineered to deliver high yield and exceptional stability in the production of recombinant proteins and plasmid DNA.

The global market for microbial-derived products and intermediates is expanding rapidly, driven by increasing demand for smaller complex biomolecules - such as antibody fragments, nanobodies, enzymes, cytokines, various antigens, polypeptides, and plasmid DNA (pDNA) - all of which present significant opportunities for the development of next-generation therapies.

To address t...